HOME > Projects > Immunity and Regeneration Integration Unit


Immunity and Regeneration Integration Unit



Establishing cancer profiling
to develop ground-breaking, innovative, personalized medicine and therapeutics

We pursued research and development of the characteristics of “cancer stem cells” by building a drug discovery/development platform that is unparalleled in the world and based on integrated cutting-edge knowledge. By distinguishing our center’s processes from the conventional linear path from basic to clinical research, we aim to accumulate multidimensional networking information, knowledge, and applications to develop and demonstrate the highest degree of academic flexibility. We plan to contribute to the industry by building highly accurate human models that precisely reflect the response of cancer stem cells to anticancer agents such as TAS102 and patients’ pathologies, innovative cancer metabolism analysis of cancer stem cells, trans-omics analysis, and highly accurate predictive molecular markers. These plans include, but are not limited to, companion drug development, next-generation nucleic acid drug development, innovative drug delivery systems, and the redevelopment of discontinued drugs.

Responsible Department

Department of Medical Data Science

Research Partners

Taiho Pharmaceutical Co., Ltd.



IDEA Consultants, Inc.

Project Members

Principal Investigator

ISHII Hideshi

Specially Appointed Professor

Department of Medical Data Science